Toward a greater appreciation of noncovalent chemical/DNA interactions: Application of biological and computational approaches
暂无分享,去创建一个
[1] Ronald D Snyder,et al. Evaluation of DNA intercalation potential of pharmaceuticals and other chemicals by cell‐based and three‐dimensional computational approaches , 2004, Environmental and molecular mutagenesis.
[2] R. Snyder,et al. Assessment of the sensitivity of the computational programs DEREK, TOPKAT, and MCASE in the prediction of the genotoxicity of pharmaceutical molecules , 2004, Environmental and molecular mutagenesis.
[3] Neal F. Cariello,et al. Comparison of the computer programs DEREK and TOPKAT to predict bacterial mutagenicity. Deductive Estimate of Risk from Existing Knowledge. Toxicity Prediction by Komputer Assisted Technology. , 2002, Mutagenesis.
[4] Ronald D Snyder,et al. Putative identification of functional interactions between DNA intercalating agents and topoisomerase II using the V79 in vitro micronucleus assay. , 2002, Mutation research.
[5] Nigel Greene,et al. Computer systems for the prediction of toxicity: an update. , 2002, Advanced drug delivery reviews.
[6] R. Snyder,et al. EVIDENCE FOR AND ROLE OF THE DIMETHYLAMINO GROUP IN TAMOXIFEN DNA INTERCALATION IN INTACT CHINESE HAMSTER V79 CELLS , 2002, Drug and chemical toxicology.
[7] Ronald D Snyder,et al. Evaluation of the clastogenic, DNA intercalative, and topoisomerase II‐interactive properties of bioflavonoids in Chinese hamster V79 cells , 2002, Environmental and molecular mutagenesis.
[8] M. Braña,et al. Intercalators as anticancer drugs. , 2001, Current pharmaceutical design.
[9] V. Steele,et al. Selection of cancer chemopreventive agents based on inhibition of topoisomerase II activity. , 2000, European journal of cancer.
[10] P Vineis,et al. Markers of DNA repair and susceptibility to cancer in humans: an epidemiologic review. , 2000, Journal of the National Cancer Institute.
[11] R. Snyder,et al. The bleomycin amplification assay in V79 cells predicts frameshift mutagenicity of intercalative agents. , 2000, Mutagenesis.
[12] R. Snyder,et al. Use of catalytic topoisomerase II inhibitors to probe mechanisms of chemical‐induced clastogenicity in Chinese hamster V79 cells , 2000, Environmental and molecular mutagenesis.
[13] L. Strekowski,,et al. Enhancement of bleomycin-induced micronucleus formation in V79 cells as a rapid and sensitive screen for non-covalent DNA-binding compounds. , 1999, Mutation research.
[14] E. D. Bransome,et al. The ligand insertion hypothesis in the genomic action of steroid hormones 1 1 Proceedings of the 13th International Symposium of the Journal of Steroid Biochemistry & Molecular Biology “Recent Advances in Steroid Biochemistry & Molecular Biology” Monaco 25–28 May 1997. , 1998, The Journal of Steroid Biochemistry and Molecular Biology.
[15] W. Denny,et al. The mutagenic properties of DNA minor-groove binding ligands. , 1996, Mutation research.
[16] P. Mosesso,et al. Report from working group on in vitro tests for chromosomal aberrations. , 1994, Mutation research.
[17] J. Lown,,et al. Minor‐groove binders are inhibitors of the catalytic activity of DNA gyrases , 1993, FEBS letters.
[18] L. EdwardsMichael,et al. Synthesis and DNA-binding properties of polyamine analogues. , 1991 .
[19] L. Strekowski,,et al. Quantitative structure-activity relationship analysis of cation-substituted polyaromatic compounds as potentiators (amplifiers) of bleomycin-mediated degradation of DNA. , 1991, Journal of medicinal chemistry.
[20] R. L. Jones,et al. The interaction of unfused polyaromatic heterocycles with DNA: intercalation, groove-binding and bleomycin amplification. , 1990, Anti-cancer drug design.
[21] W. Denny. DNA-intercalating ligands as anti-cancer drugs: prospects for future design. , 1989, Anti-cancer drug design.
[22] M. McHugh,et al. Modulation of topoisomerase II catalytic activity by DNA minor groove binding agents distamycin, Hoechst 33258, and 4',6-diamidine-2-phenylindole. , 1989, Molecular pharmacology.
[23] L. Strekowski,,et al. Binding of unfused aromatic cations to DNA. The influence of molecular twist on intercalation , 1988 .
[24] L. Strekowski,,et al. Molecular basis for bleomycin amplification: conformational and stereoelectronic effects in unfused amplifiers. , 1988, Journal of medicinal chemistry.
[25] L. Strekowski,,et al. Amplification of bleomycin-mediated degradation of DNA. , 1987, Journal of medicinal chemistry.
[26] J. Ashby. Fundamental structural alerts to potential carcinogenicity or noncarcinogenicity. , 1985, Environmental mutagenesis.
[27] L. Ferguson,et al. Comparison of the mutagenic and clastogenic activity of amsacrine and other DNA-intercalating drugs in cultured V79 Chinese hamster cells. , 1984, Cancer research.
[28] W. Denny,et al. Potential antitumor agents. 30. Mutagenic activity of some 9-anilinoacridines: relationships between structure, mutagenic potential, and antileukemic activity. , 1979, Journal of medicinal chemistry.
[29] L. Hendry,et al. Gene Regulation: The Involvement of Stereochemical Recognition in DNA-Small Molecule Interactions , 2015, Perspectives in biology and medicine.